Yes
| Award | Tuition Fees | Attendance Mode | Length of Course |
|---|---|---|---|
| MSc | 2012/13
(A small increase can be expected for the subsequent year) |
Full-time | 12 months
September |
Based upon a greater understanding of the molecular aspects of cancer, new opportunities for therapeutic intervention have emerged that are effectively 'target orientated'. These new therapeutics are quite distinct from the classical chemotherapeutic agents and they offer the prospect of truly selective cancer therapies that are tailored towards the individual patient's tumour. This is an exciting time to be involved in cancer therapeutics and cancer pharmacology plays a key role in drug development. In both the laboratory and the clinic, cancer pharmacology has had to adapt to the changing face of drug development by establishing experimental models and target orientated approaches.
The programme is designed to provide you with a 'state-of-the-art' course in modern cancer pharmacology that meets the demand of employers and an expert view of the available cancer medicines and the development of new cancer therapies.
It promotes advanced scholarship within specialised areas at the same time as the development of key transferable skills (in IT and bioinformatics) and research techniques.
2011/12: All Modules are Core
Semester 1 (60 Credits - 4 Modules):
Semester 2 (60 Credits - 4 Modules):
End of Semester 2 onwards (60 Credits - 1 Module);
IELTS at 6.0 or the equivalent.
[Full information on our General English Language Requirements]
Visit the Institute of Cancer Therapeutics website for student quotes and video testimonials at www.cancer.brad.ac.uk/postgraduate-study.
School of Life Sciences Postgraduate Admissions Administrator (Master's courses)
Life Sciences School Prospectus 2012 (PDF 5MB)
Please note that these PDFs are correct as at time of print (November 2011). For the most up to date course information please use the web page.